PM
STLN

Prosight Management’s Starling Oncology STLN Stock Holding History

Prosight Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-455,302
Closed -$251K – 47
2023
Q2 		$251K Buy
455,302
+173,400
+62% +$91.7K 0.07% 35
2023
Q1 		$191K Buy
281,902
+6,341
+2% +$8.09K 0.09% 39
2022
Q4 		$455K Buy
+275,561
New +$773K 0.25% 38

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Prosight Management's STLN Position: Q3 2023 in Review

Prosight Management sold out of Starling Oncology (STLN) in Q3 2023, closing a stake of 455,302 shares — an estimated $251K sold.

Prosight Management first reported a position in STLN in Q4 2022 and held it in 3 quarters. The position peaked at $455K in Q4 2022. 36 funds tracked by Wall St. Rank hold STLN as of Q3 2023.

  • Prosight Management reported no remaining Starling Oncology position as of Q3 2023 after selling out during the quarter.
  • Prosight Management sold 455,302 Starling Oncology shares in Q3 2023, an estimated $251K.
  • Prosight Management first reported a position in Starling Oncology in Q4 2022 and held it in 3 quarters.
  • Prosight Management's Starling Oncology position peaked at $455K in Q4 2022.
  • 36 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2023.

Based on Prosight Management's 13F filing for Q3 2023, filed 14 Nov 2023.